ALLO - Allogene Therapeutics, Inc.

QQQ $ 629.78 $ -3.11 (-0.49 %)

DIA $ 472.70 $ -2.66 (-0.56 %)

SPY $ 681.88 $ -2.29 (-0.33 %)

TLT $ 89.68 $ 0.07 (0.08 %)

GLD $ 366.72 $ 0.05 (0.01 %)

Previous Close

$ 1.18

Open

$ 1.25

Bid

$ 1.16 x 69

Ask

$ 1.27 x 4,955

Day's Range

$ 1.17 - $ 1.26

52 Week Range

$ 0.86 - $ 3.78

Volume

2,098,226

Average Volume

Market Cap

261.82M

Beta (5Y Monthly)

$ 1.40

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-13-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-13-2024	03-31-2024	10-Q
7	03-14-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-02-2023	06-30-2023	10-Q
10	05-03-2023	03-31-2023	10-Q
11	02-28-2023	12-31-2022	10-K
12	11-02-2022	09-30-2022	10-Q
13	08-09-2022	06-30-2022	10-Q
14	05-04-2022	03-31-2022	10-Q
15	02-23-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-04-2021	06-30-2021	10-Q
18	05-05-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-04-2020	09-30-2020	10-Q
21	08-05-2020	06-30-2020	10-Q
22	05-06-2020	03-31-2020	10-Q
23	02-27-2020	12-31-2019	10-K
24	11-05-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	03-08-2019	12-31-2018	10-K
28	11-21-2018	09-30-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-keysight-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday

This Keysight Analyst Is No Longer Bullish...
10/10/2025 13:53:02

JP Morgan Downgrades Allogene Therapeutics...
10/10/2025 11:38:49

JP Morgan analyst Brian Cheng downgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Underweight.

Allogene Therapeutics Q2 EPS $(0.23) Beats...
08/13/2025 20:38:42

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of...

Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

A Look at Allogene Therapeutics's Upcoming...
08/12/2025 18:02:55

JMP Securities Reiterates Market Perform o...
08/04/2025 14:28:24

JMP Securities analyst Reni Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Market Perform.

this-avalonbay-communities-analyst-is-no-longer-bullish-here-are-top-4-downgrades-for-monday

This AvalonBay Communities Analyst Is No L...
08/04/2025 11:47:31

JP Morgan Downgrades Allogene Therapeutics...
08/04/2025 10:00:46

JP Morgan analyst Brian Cheng downgrades Allogene Therapeutics (NASDAQ:ALLO) from Overweight to Neutral.

allogene-resets-clinical-course-after-patient-death-in-lymphoma-study

Allogene Resets Clinical Course After Pati...
08/01/2025 16:52:06

Allogene revised its LBCL trial after a fatal adverse event linked to ALLO-647, shifting to a standard FC regimen and updating ...

Allogene Therapeutics FC Plus ALLO-647 Arm...
08/01/2025 13:32:00

-SEC Filing

Allogene Therapeutics Selects Selected Sta...
08/01/2025 12:37:24

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Comm...

12 Health Care Stocks Moving In Friday's P...
07/25/2025 12:08:49

Reported Sunday, Allogene Reports 31% Conf...
06/02/2025 06:57:54

Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Me...

Allogene Therapeutics Reveals ASCO 2025 Ab...
05/22/2025 21:28:30

Citigroup Maintains Buy on Allogene Therap...
05/15/2025 14:37:18

Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target fro...

Truist Securities Maintains Buy on Allogen...
05/14/2025 16:07:38

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price...

Piper Sandler Maintains Overweight on Allo...
05/14/2025 16:04:34

Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and lowers the price target...

RBC Capital Reiterates Outperform on Allog...
05/14/2025 15:08:05

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.

Oppenheimer Maintains Outperform on Alloge...
05/14/2025 14:29:42

Oppenheimer analyst Matthew Biegler maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price tar...

Baird Maintains Outperform on Allogene The...
05/14/2025 13:12:58

Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $...